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Abstract
DNA methylation is a defining feature of mammalian cellular identity and essential for normal
development1,2. Most cell types, except germ cells and pre-implantation embryos3–5, display
relatively stable DNA methylation patterns with 70–80% of all CpGs being methylated6. Despite
recent advances we still have a too limited understanding of when, where and how many CpGs
participate in genomic regulation. Here we report the in depth analysis of 42 whole genome
bisulfite sequencing (WGBS) data sets across 30 diverse human cell and tissue types. We observe
dynamic regulation for only 21.8% of autosomal CpGs within a normal developmental context, a
majority of which are distal to transcription start sites. These dynamic CpGs co-localize with gene
regulatory elements, particularly enhancers and transcription factor binding sites (TFBS), which
allow identification of key lineage specific regulators. In addition, differentially methylated
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regions (DMRs) often harbor SNPs associated with cell type related diseases as determined by
GWAS. The results also highlight the general inefficiency of WGBS as 70–80% of the sequencing
reads across these data sets provided little or no relevant information regarding CpG methylation.
To further demonstrate the utility of our DMR set, we use it to classify unknown samples and
identify representative signature regions that recapitulate major DNA methylation dynamics. In
summary, although in theory every CpG can change its methylation state, our results suggest that
only a fraction does so as part of coordinated regulatory programs. Therefore our selected DMRs
can serve as a starting point to help guide novel, more effective reduced representation approaches
to capture the most informative fraction of CpGs as well as further pinpoint putative regulatory
elements.
Changes in DNA methylation (DNAme) patterns and the resulting differentially methylated
regions (DMR) have been the focus of numerous studies in the context of normal
development7 and disease8. These studies have characterized many different DMR classes
including partially methylated domains (PMDs)9, condition specific10, cell type
specific9,11–13 and tissue specific DMRs14,15 (tDMRs) as well as DMRs arising in disease
such as cancer15,16. Due to the relatively small fraction of genomic CpGs assayed or small
sample cohorts, the question of what fraction of genomic CpGs changes its methylation state
in the context of normal development as well as their regulatory context remains
underexplored.
In this study, we systematically investigated the DNAme state of most human autosomal
CpGs to determine those that show dynamic changes and hence may participate in genome
regulation in a developmental context (dynamic CpGs). In total, we included 42 WGBS
datasets comprising a range of human cell and tissue types (n=30). The combined 40.4
billion reads enabled us to assay 25.71 million autosomal CpGs (≥5× coverage in at least
≥50% of all samples; 96% of all hg19 autosomal CpGs) (Supplementary Table 1). We
organized the samples into four classes; comprising human embryonic stem cells (hESCs),
hESC derived cell populations, normal somatic tissues as well as disease conditions (Fig. 1a,
Supplementary Table 1). On a global scale, hESC and their derivatives exhibit the highest
DNAme levels, followed by primary tissues (~5% less), which is in sharp contrast to the
global hypomethylation in colon cancer (~10–15% less) and long-term cultured cell lines
(10–30% less).
Focusing initially on our developmental sample set (n=24 total, hESCs, in vitro derived cell
types and somatic tissues, Supplementary Table 1) we identified ~5.6 million dynamic CpGs
(minimum methylation difference ≥0.3, FDR=10.4%, 21.8% of captured autosomal CpGs;
Fig. 1b, Supplementary Fig. 1e, see Supplementary Information) distributed across 716,087
discrete differentially methylated genomic regions (DMRs, 19.2% of the mappable human
genome). In addition to this moderately stringent cutoff, we also tested thresholds as low as
10% methylation difference that may account for DNAme changes arising from relevant
small subpopulations in heterogeneous tissue samples or noise, but still only find 10.4
million CpGs to be dynamic.
Focusing on the more stringent set (≥0.3 difference), we find approximately 70% are on
average highly methylated (>75% methylation ratio) while less than 2% are on average
unmethylated (<10% methylation ratio) (Supplementary Fig. 1h). In line with this
observation, we find that hypomethylation of DMRs shows greater sample specificity than
hypermethylation (Fig. 1c). Interestingly, most of the DMRs are small (>75% are smaller
than 1kb, Supplementary Fig. 1i) and located distal to transcription start sites (TSS)
(Supplementary Fig. 1j). However, the average variation in DNAme levels across all RefSeq
promoters (n=30,090) does still exhibit a clear increase specifically at the TSS with most of
this variation occurring at intermediate and low CpG density promoters (Fig. 1d). For CpG
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islands in general, we observe distinct dynamic regimes, highlighting that different classes
of CpG islands are likely subject to different modes of regulation12,17,18 (Fig. 1d bottom).
Consistent with previous reports15, we find CpG island shores to be among the most
variable genomic regions (Supplementary Fig. 1o). These observations are exemplified at
the OCT4 (POU5F1) locus, where the promoter and large parts of the gene body exhibit
high DNAme dynamics, while the strong downstream CpG island as well as the surrounding
CTCF binding sites remain static (Fig. 1e). Only 12.2% of our DMR set overlap with at least
one of 568,430 annotated classic, gene centric genomic features (promoter, exon, CGI, CGI-
shore) (Fig. 1f). To gain insights into the role of the remaining set, we first investigated their
co-localization with DNase I HS sites across 92 distinct cell types19 as well as a catalog of
putative enhancer elements for 31 cell and tissue types20. Strikingly, we found that 42.3% of
our DMRs overlap with at least one DNAse I HS site (Fig. 1f) and 26.1% co-localize with
enhancer like regions, which cover more than 50% of all H3K27ac regions in our catalog
(n=285,344) and represents one of the most differentially methylated features (Fig. 1d).
Next, we examined DMR overlap with transcription factor binding site (TFBS) clusters
determined by the ENCODE project21 and uncovered a highly significant overlap of the two
feature classes (jaccard=0.11, p-value<=0.1). Taking into account an even broader set of
TFBS comprising 165 factors,, we find that more than 50% of all DMRs overlap with at
least one and 25% with more than 3 TFBS accounting for an additional 13.0% of DMRs
(Fig. 2a). Consistent with this we find dramatically increased variation in DNAme levels
specifically across TFBS (Supplementary Fig. 2a). In summary, we were able to readily
attribute 64.2% of all DMRs to at least one putative gene regulatory element or coding
sequence (Supplementary Fig. 1e–h) suggesting they demarcate various classes of putative
regulatory elements.
We determined all cell type specific hypomethylated regions (n=430,250, see
Supplementary Information) and investigated the enrichment for 161 ENCODE factors
(excluding MBD4, SETDB1, POL2P, HDAC2 from the prior set). Strikingly, we observe
significant enrichment of cell type specific TFs that are known to be involved in the
regulation of the respective cellular states (Fig. 2b). For instance, the top three factors bound
in HUES64 specific DMRs are OCT4, SOX2, and NANOG (Fig. 2b). Similarly, PU.1 and
TAL1 are highly enriched in CD34 cells and HNF factors in adult liver (Fig. 2b). In further
support of this, motif enrichment analysis revealed many more interesting cell-type-TF-
associations such as enrichment of distinct NKX factors in fetal heart and fetal brain as well
as ESRRG in fetal adrenal cells (Supplementary Fig. 2b, Supplementary Table 3).
Moreover, we tested whether the DMR set can be used to gain insights into the
combinatorial control of cellular states by TFs. To that end, we determined all unmethylated
(<10% methylation) PAX5 motif instances (±100bp) across the human genome in CD34 or
fetal brain cells (Fig. 2c). While, both footprint sets show a large overlap (11,031 sites),
regions exclusively unmethylated in CD34 or fetal brain are enriched for distinct sets of
other known lineage specific TF motifs; such as PU.1 in CD34 and LMX1A or EN1 in fetal
brain (Fig. 2c). Taken together, these findings highlight that cell type specific DNAme
patterns can be used to detect footprints and infer potentially regulatory TFs. In fact, more
than 60% of all ENCODE TFBS are hypermethylated in most samples, but become
hypomethylated very specifically in only one or two cell types (Fig. 2d), while 25% are
constitutively unmethylated and never change (Fig. 2d).
Breaking down this distribution of TFBS reveals distinct patterns of variation for different
types of TFs (Supplementary Fig. 2e). More generally, we find that DNAme variation across
TFBS is strongly correlated with its median methylation level and therefore the (hypo-)
methylation specificity (Supplementary Fig. 2c), as well as the TFs specificity of
expression22 (Supplementary Fig. 2d). These observations support the notion23 that selective
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TF binding creates spatially highly constrained hypomethylated regions and confers cell
type specificity.
Based on these findings and previous reports24 we asked whether DMRs are more
susceptible to point mutations that are functionally consequential. Even with strict filtering
criteria, we found a significant enrichment of SNPs in DMRs compared to genomic
background as well as different sets of random control regions (odds ratio 1.06, p-
value<10−16, binomial test, Supplementary Information). We then determined the overlap of
DMRs with recently evolved human specific CpGs, termed CpG beacons25, which shows a
striking enrichment (odds ratio 1.37–1.6 compared to genomic background and random
control regions, p-value<10−16). This suggests overall higher genetic intra-species
variability specifically at regions that change their DNAme state. In concordance with the
increased SNP frequency, DMRs are also significantly enriched for GWAS SNPs from the
GWAS catalog26 (odds ratio 1.16, p-value=3.27×10−10, binomial test). Similar to our
observations on TFBS, GWAS SNPs exhibit a non-random enrichment distribution across
cell type specific DMRs (Fig. 3a). For instance, we find DMRs specific to adult liver to be
enriched for liver and serum metabolite related GWAS SNPs, fetal heart for cardiovascular
and many of our blood cell types for autoimmune diseases and hematological parameters.
It is well known that many cancers exhibit dramatic DNAme changes27, we therefore
compared a colon cancer to a matched control and found 532,665 differentially methylated
CpGs. 40% of these overlapped with the previously identified developmental dynamic set
(Fig. 4a). Similarly, 36% of differentially methylated CpGs found in Alzheimer Disease
(AD) samples compared to normal controls (n=12,408) overlapped with our previous set of
developmental CpGs. The most dramatic change in the number of dynamic CpGs occurs
when comparing our developmental sample cohort to the long-term cell culture cohort,
leading to the identification of 8.4 million additional dynamic CpGs (Fig. 4b). Importantly,
this expanded set differs notably in terms of their sequence features, with cancer and AD
dynamic CpGs residing in less conserved regions that also exhibit lower motif complexity
compared to the developmental and cell culture (Supplementary Fig 4a,b). The cell culture
specific CpGs exhibit elevated repeat content relative to developmental CpGs, a feature that
is shared with AD (Fig. 4c). While the disease samples clearly add more dynamic CpGs, our
analysis suggests a notable overlap with our prior set for CpGs that may participate in actual
regulatory events.
Finally, we investigated the utility and power of the reduced region set to accurately classify
unknown samples or help deconvolute a mixture of samples. We first clustered our
developmental sample set based on the DMRs only (Fig. 4d) and found the result to be in
excellent agreement with genome-wide 1kb tiling based clustering (Supplementary Fig. 5a).
To probe the potential of our DMR set to accurately classify unknown samples, we derived
signature region sets for different sample groups. These signature regions turned out to be
excellent classifiers of an unseen sample (fetal brain, Fig. 4e). Next, we tested as a proof of
principle whether it is possible to utilize our DMR set to infer the different cell populations
present within a heterogeneous sample. To that end, we deconvoluted an in silico mixture of
HUES64 and hippocampus WGBS libraries using our DNAme signatures. Notably, the two
top hits after application of a very simple deconvolution algorithm indeed proved to be
hippocampus and HUES64 (Fig. 4f).
Our study highlights and defines a relatively small subset of all genomic CpGs that change
their DNA methylation state across a large number of representative cell types. Although we
expect that number to somewhat increase with more diverse cell types as more WGBS data
sets becoming available, our analysis suggests that the rate of newly discovered regulatory
CpGs will drop rapidly once all major cell and tissue types have been mapped, mostly owed
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to the fact that between tissue variability exceeds within tissue variability by one order of
magnitude (Supplementary Fig. 3a,b). Future studies are likely to fine map dynamics
occurring in more specific subpopulations, giving rise to smaller changes in DNAme that we
were unable to detect or include because of power constraints. Extreme conditions in vitro or
in vivo such as loss or misregulation of DNMT1 may affect a larger subset including many
intergenic CpGs that are generally static, but most of these additional CpGs are unlikely to
overlap with functional elements such as TFBS or enhancers. In combination with the fact
that sequencing of WGBS libraries is very inefficient, as about 65% of all 101bp reads in
our set did not even contain any CpGs to begin with, this amounts to an approximate,
combined loss of around 80% of sequencing depth on non-informative reads and static
regions. Finally, once defined, it will likely be sufficient in most cases to profile only a
representative subset of CpGs across a comprehensive set of DMRs using an array28 or
hybrid capture29 based technology to recover representative dynamics and measure
regulatory events. Using these results as a guiding principle, we expect further improved
efficiencies in mapping DNAme and enhance its applicability as a marker for various
regulatory dynamics in normal and disease phenotypes.
Methods Summary
Biological materials and sequencing libraries
Genomic DNA was fragmented to 100–500 bp using a Covaris S2 sonicator. DNA
fragments were cleaned-up, end-repaired, A-tailed, and ligated with methylated paired-end
adapters (purchased from ATDBio). See Supplementary Information for details.
Data processing and analysis
In house generated WGBS libraries were aligned using MAQ30 in bisulfite mode to the
hg19/GRCh37 reference assembly. Subsequently, CpG methylation calls were made using
custom software, excluding duplicate, low quality reads as well as reads with more than
10% mismatches. Methylation ratios of individual CpGs were modeled using a beta-
binomial model estimating parameters from the number of methylated and total reads
overlapping a given CpG, incorporating replicates. Only CpGs covered by ≥5× reads were
considered for further analysis. Differential methylation values of individual CpGs were
estimated using the beta-difference distributions. CpG cluster differential methylation was
determined by pooling CpG level methylation differences using a random effects model.
CpG cluster methylation specificity was determined using the Jensen-Shannon divergence of
a CpG cluster’s methylation level distribution across all samples and a reference distribution
representing either of the two extremes: completely unmethylated or fully methylated. In
silico identified CpG islands were defined by genomic regions of at least 700bp length, an
CpG observed vs. expected ratio of greater than 0.6 and a GC content greater or equal than
0.5. For the SNP analysis, we obtained the CEPH SNP set from USCS. GWAS SNPs were
retrieved from the GWAS catalog, while most of the GWAS SNP grouping was taken from
Maurano et al.24. For TFBS analysis, we retrieved peak files from the ENCODE projects
and collapsed replicates. Motif analysis was carried out using FIMO.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Identification and characteristics of differentially methylated regions (DMRs) in the
human genome
a. Principal component analysis based on CpG methylation levels for 1kb tiles across 30
diverse human cell and tissue samples. Coloring indicates classification of samples into
subgroups and group wise mean DNAme. Detailed sample annotations are listed in
Supplementary Table 1. Gray area indicates Alzheimer’s disease (AD) samples..
b. Density scatterplot of CpG wise DNAme level differences (x-axis, p≤0.01) and CpG
median methylation (y-axis) across the 24 developmental samples (excluding cancer and
long-term culture). Coloring indicates CpG density from low (blue) to high (red). The red
box highlights dynamic CpGs (≥0.3).
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c. Cumulative distribution of DMR specificity. High hypo/hypermethylation specificity
indicates that particular region is methylated/unmethylated in most tissues and deviates from
this default state in only one or few cases.
d. Top: Composite plot of mean DNAme differences across various genomic features. Black
line indicates the median of the average DNAme difference across each feature. Grey areas
mark 25th and 75th percentile. Bottom: Distribution of mean DNAme difference for each
genomic feature. Black bar indicates 25th and 75th percentile while white dot marks the
median. For CGI islands, a smaller, experimentally determined set (eCGI; n=25,490) is
shown as well. Promoters are broken down into high CpG content (HCP, n=24,899),
intermediate CpG content (ICP, n=10,920) and low CpG content (LCP, n=7,946) regions
(n=43,765 total).
e. Methylation level variation across the OCT4 locus (chr6:31,119,000–31,162,000) (top).
Blue boxes indicate DMRs significant at p≤0.01 and exhibit a minimum difference ≥0.3
across the 24 developmental samples. For reference, ENCODE TFBS cluster track, DNAse I
hypersensitive sites, CpG islands and RefSeq genes are shown.
f. Distribution of DMRs across various genomic features. Each region is assigned only to
one of these genomic feature according the ranking promoter, CGI, CGI shore, exon, intron,
putative enhancers, DNAse I hypersensitive site or other.
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Figure 2. Dynamic CpG methylation regions frequently co-localize with transcription factor
binding sites (TFBS)
a. Overlap of DMRs with ENCODE TFBS.
b. Enrichment of the top four TFBSs significantly overrepresented (p<0.01, empirical test)
in DMRs specific to the cell type indicated (specificity >0.15). Color code quantifies median
enrichment odds ratio compared to size matched random control regions.
c. Overlap of PAX5 motifs (±100bp top) unmethylated in CD34 cells or fetal brain across
the entire human genome. Regions specifically unmethylated in CD34 or fetal brain were
subjected to motif analysis and top differentially co-occurring motifs are highlighted on the
left for CD34 and on the right for fetal brain.
d. Density scatterplot of maximum DNAme difference across 24 developmental samples for
TFBS cluster track (n=2.7 million) and median methylation level across all samples. Color
code indicates density of TFBS from low (blue) to high (red)..
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Figure 3. DMRs exhibit elevated SNP frequency and show non-random GWAS SNP enrichment
a. Odds ratio of significantly overrepresented (p<0.05, empirical test, see Supplementary
Information) GWAS SNPs grouped into 16 categories in regions specifically
hypomethylated within the sample indicated on the left. Asterisk indicates p-value <0.1.
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Figure 4. Effective classification and sample deconvolution using only the DMR set
a. Overlap of dynamic CpGs (p≤0.01 Δ≥0.3) in normal samples and between colon cancer
and matching control CpG numbers (in million).
b. Distribution of autosomal CpGs across three conditions. Class name indicates sample
group where a CpG was observed dynamic (developmental (n=24), cell culture (n=3),
cancer (n=2)) or remained unchanged over the entire sample set (n=30).
c. Repeat content distribution of DMRs (sets as in b).
d. Hierarchical clustering using pearson correlation coefficient (PCC) of the DMR values
across the entire sample set (n=30).
e. Distance of the fetal brain sample to different sets of signature regions defined for sample
classes or individual samples, but excluding regions identified by means of the fetal brain
sample.
f. Contribution of individual sample signature region sets to an in silico generated hybrid
sample (HUES64 and hippocampus).
Ziller et al. Page 12
Nature. Author manuscript; available in PMC 2014 February 22.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
